These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Inhibition of thromboxane synthesis and platelet aggregation by pyridine and its derivatives. Tai HH; Lee N; Tai CL Adv Prostaglandin Thromboxane Res; 1980; 6():447-52. PubMed ID: 7189951 [TBL] [Abstract][Full Text] [Related]
3. [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Nakazawa M; Iizuka K; Ujiie A; Hiraku S; Ohki S Yakugaku Zasshi; 1994 Dec; 114(12):911-33. PubMed ID: 7869235 [TBL] [Abstract][Full Text] [Related]
12. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds. Main AJ; Goldstein R; Cohen DS; Furness P; Lee W J Med Chem; 1992 Nov; 35(23):4362-5. PubMed ID: 1447736 [TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Harada K; Miyamoto K; Yamatsu I J Med Chem; 1996 Aug; 39(16):3148-57. PubMed ID: 8759636 [TBL] [Abstract][Full Text] [Related]
14. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis. Vanden Bossche H; Willemsens G; Bellens D; Janssen PA Biochem Pharmacol; 1992 Feb; 43(4):739-44. PubMed ID: 1540227 [TBL] [Abstract][Full Text] [Related]
15. Thromboxane synthetase inhibitors: design and synthesis of a novel series of omega-pyridylalkenoic acids. Terao S; Kato K; Ohkawa S; Terashita Z; Nishikawa K Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():315-7. PubMed ID: 2936112 [No Abstract] [Full Text] [Related]
16. Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. VI. Indazole derivatives. Yamaguchi M; Maruyama N; Koga T; Kamei K; Akima M; Kuroki T; Hamana M; Ohi N Chem Pharm Bull (Tokyo); 1995 Feb; 43(2):332-4. PubMed ID: 7728936 [TBL] [Abstract][Full Text] [Related]
17. Correlative alteration of thromboxane A2 with antigen-induced bronchoconstriction and the role of platelets as a source of TXA2 synthesis in guinea pigs: effect of DP-1904, an inhibitor of thromboxane synthetase. Takami M; Tsukada W Pharmacol Res; 1998 Aug; 38(2):133-9. PubMed ID: 9721601 [TBL] [Abstract][Full Text] [Related]
18. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
19. 9,11-Iminoepoxyprosta-5,13-dienoic acid is a selective thromboxane A2 synthetase inhibitor. Fitzpatrick F; Gorman R; Bundy G; Honohan T; McGuire J; Sun F Biochim Biophys Acta; 1979 May; 573(2):238-44. PubMed ID: 375987 [TBL] [Abstract][Full Text] [Related]
20. Effects of thromboxane synthase inhibitors on renal function. Jackson EK; Goto F; Uderman HD; Workman RJ; Herzer WA; FitzGerald GA; Branch RA Naunyn Schmiedebergs Arch Pharmacol; 1988 Feb; 337(2):183-90. PubMed ID: 3285227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]